HC Wainwright Comments on Sutro Biopharma FY2030 Earnings

Sutro Biopharma, Inc. (NASDAQ:STRO) – HC Wainwright issued their FY2030 earnings estimates for shares of Sutro Biopharma in a research report issued to clients and investors on Tuesday, March 24th. HC Wainwright analyst A. Maldonado expects that the company will post earnings of ($4.43) per share for the year. HC Wainwright has a “Buy” rating and a $28.00 price objective on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($2.92) per share.

Several other research analysts have also weighed in on STRO. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Monday, December 22nd. Wells Fargo & Company upgraded Sutro Biopharma from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $8.00 to $27.00 in a research report on Tuesday. Truist Financial raised Sutro Biopharma to a “strong-buy” rating in a research note on Wednesday. Citigroup upgraded Sutro Biopharma to an “outperform” rating in a report on Tuesday, January 20th. Finally, Wedbush reissued a “neutral” rating and set a $100.00 price objective (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $37.29.

Sutro Biopharma Stock Performance

STRO stock opened at $24.91 on Wednesday. The firm has a market cap of $212.08 million, a PE ratio of -0.95 and a beta of 1.47. The firm’s 50 day moving average price is $18.84 and its 200-day moving average price is $12.84. Sutro Biopharma has a one year low of $5.23 and a one year high of $26.54.

Institutional Trading of Sutro Biopharma

Several institutional investors have recently added to or reduced their stakes in the stock. State of Tennessee Department of Treasury purchased a new stake in Sutro Biopharma in the fourth quarter valued at approximately $86,000. Jane Street Group LLC acquired a new position in Sutro Biopharma during the fourth quarter worth $265,000. Bridgeway Capital Management LLC boosted its position in shares of Sutro Biopharma by 232.6% during the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after buying an additional 30,000 shares during the period. ADAR1 Capital Management LLC purchased a new position in shares of Sutro Biopharma during the fourth quarter worth $776,000. Finally, Spruce Street Capital LP acquired a new stake in shares of Sutro Biopharma in the fourth quarter valued at $875,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

Key Headlines Impacting Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target to $55 from $51 and maintained a “Buy” rating — a sizable upside vs. the current price, which supports bullish sentiment. Benzinga
• Positive Sentiment: Truist Financial upgraded Sutro to “Strong-Buy,” reinforcing buy-side momentum among institutional analysts. Zacks
• Positive Sentiment: Wells Fargo upgraded STRO to “Overweight,” adding another supportive brokerage view that can attract investors. Wells Fargo Upgrade
• Positive Sentiment: HC Wainwright also issued an upgrade/coverage item (Buy, $28 PT) in recent press coverage, adding to the cluster of buy-side recommendations. AmericanBankingNews – HC Wainwright Upgrade
• Neutral Sentiment: HC Wainwright published a FY2030 estimate (EPS forecast of ($4.43)), which is informational for longer-term modeling but not a catalyst on its own. MarketBeat
• Negative Sentiment: Offsetting the upgrades, HC Wainwright sharply lowered near- and multi-year EPS forecasts across Q1–Q4 2026 and FY2026–FY2029 (e.g., FY2026 cut to ($10.32) from ($4.25); FY2027–FY2029 also pushed materially lower), while retaining a Buy rating and $28 PT — these large downside revisions imply greater near-term dilution, higher cash burn or program changes and represent a negative earnings/cash-flow signal investors should model into valuations. MarketBeat – Estimates

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.